| Quarterly Financials | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 188 | 208 | 190 | 189 | 192 | 237 | 213 | 215 | 251 | 267 | 259 | 223 | 275 | 286 | 270 | 243 | 289 | 327 | 308 | 277 | 350 | 360 | 333 | 309 | 395 | 461 | 420 | 398 | 461 | 504 | 488 | 562 | 717 | 744 | 726 | 711 |
| Expenses | 109 | 125 | 112 | 135 | 114 | 152 | 128 | 141 | 162 | 164 | 159 | 153 | 170 | 175 | 190 | 171 | 189 | 205 | 203 | 184 | 223 | 220 | 210 | 209 | 269 | 309 | 286 | 284 | 297 | 324 | 311 | 403 | 470 | 477 | 477 | 453 |
| EBITDA | 79 | 83 | 78 | 54 | 78 | 86 | 85 | 75 | 88 | 103 | 100 | 70 | 105 | 111 | 81 | 72 | 100 | 122 | 105 | 93 | 127 | 141 | 123 | 100 | 125 | 151 | 134 | 114 | 164 | 180 | 177 | 160 | 248 | 267 | 249 | 258 |
| Operating Profit % | 40 % | 37 % | 39 % | 27 % | 39 % | 34 % | 38 % | 32 % | 34 % | 37 % | 36 % | 28 % | 38 % | 38 % | 28 % | 30 % | 34 % | 37 % | 33 % | 33 % | 35 % | 38 % | 36 % | 31 % | 31 % | 32 % | 32 % | 28 % | 35 % | 35 % | 36 % | 26 % | 34 % | 35 % | 34 % | 36 % |
| Depreciation | 5 | 5 | 6 | 7 | 5 | 5 | 7 | 9 | 7 | 8 | 10 | 11 | 12 | 12 | 13 | 14 | 10 | 11 | 11 | 12 | 15 | 15 | 17 | 18 | 23 | 29 | 30 | 35 | 41 | 42 | 46 | 54 | 76 | 81 | 81 | 77 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 8 | 7 | 6 | 5 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 3 | 9 | 17 | 16 | 18 | 33 | 60 | 60 | 57 | 54 |
| Profit Before Tax | 73 | 78 | 72 | 48 | 74 | 99 | 77 | 62 | 78 | 92 | 89 | 58 | 95 | 103 | 72 | 62 | 95 | 116 | 99 | 85 | 117 | 131 | 109 | 85 | 101 | 121 | 107 | 76 | 113 | 126 | 116 | 77 | 115 | 129 | 116 | 129 |
| Tax | 11 | 8 | 4 | 1 | 3 | 6 | 3 | 6 | 6 | 7 | 9 | 4 | 11 | 10 | 9 | 5 | 6 | 8 | 9 | 17 | 10 | 12 | 8 | 5 | 8 | 2 | 6 | 14 | 19 | 4 | 14 | -3 | 26 | 33 | 29 | 27 |
| Net Profit | 63 | 69 | 68 | 47 | 71 | 93 | 75 | 56 | 72 | 86 | 80 | 54 | 84 | 93 | 64 | 56 | 89 | 108 | 90 | 68 | 107 | 118 | 101 | 80 | 93 | 119 | 100 | 62 | 94 | 122 | 102 | 80 | 89 | 96 | 87 | 102 |
| EPS in ₹ | 45.64 | 5.02 | 4.95 | 3.43 | 5.15 | 6.75 | 5.43 | 4.06 | 5.18 | 6.20 | 5.83 | 3.93 | 6.11 | 6.74 | 4.62 | 4.13 | 6.56 | 7.93 | 6.64 | 5.03 | 7.86 | 8.71 | 7.41 | 5.91 | 6.96 | 8.84 | 7.49 | 4.81 | 6.97 | 9.08 | 7.55 | 5.22 | 6.11 | 6.73 | 6.16 | 6.90 |
Eris Lifesciences
1,748.80
+2.30
(0.13%)
Market Cap
23,818.19 Cr
EPS
25.85
PE Ratio
67.88
Dividend Yield
0.42 %
Industry
Healthcare52 Week High
1,910.00
52 Week Low
987.10
PB Ratio
8.33
Debt to Equity
0.97
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,725.40 | #1 4,13,981.26 | 35.23 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 52.11 | |
6,755.50 | 1,79,337.30 | 82.19 | 9,360.00 | 0.89 | 2,117 | 23.05 | 53.82 | |
1,490.20 | 1,20,364.62 | 23.31 | 28,409.50 | 7.12 | 5,291 | 30.28 | 44.66 | |
3,437.90 | 1,16,354.16 | 60.20 | 11,539.40 | 11.59 | 1,911 | 10.91 | 62.33 | |
2,647.90 | 1,09,286.45 | 56.09 | 12,207.40 | 19.57 | 1,925 | -10.91 | 76.79 | |
1,256.10 | 1,04,830.47 | #1 18.82 | 33,741.20 | 12.36 | 5,725 | 21.14 | 38.64 | |
973.25 | 97,931.72 | 20.87 | 22,573.80 | 13.82 | 3,977 | -0.19 | 49.02 | |
1,955.10 | 89,288.53 | 26.79 | 22,192.10 | #1 19.94 | 3,024 | #1 112.49 | 44.79 | |
34,335.00 | 72,959.48 | 51.66 | 6,409.15 | 10.80 | 1,417 | 27.83 | 59.37 | |
1,154.20 | 67,036.12 | 19.14 | 31,378.10 | 17.55 | 3,366 | -0.50 | 48.47 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
19.85 %
Net Income Growth
6.12 %
Cash Flow Change
119.13 %
ROE
-26.88 %
ROCE
-14.45 %
EBITDA Margin (Avg.)
6.41 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,041 | 7,033 |
| Fixed Assets | 65 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,307 |
| Current Assets | 237 | 216 | 299 | 582 | 480 | 467 | 627 | 765 | 2,302 | 1,223 |
| Capital Work in Progress | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 |
| Investments | 144 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 |
| Other Assets | 190 | 192 | 324 | 435 | 595 | 685 | 807 | 1,041 | 2,686 | 1,593 |
| Total Liabilities | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,041 | 7,033 |
| Current Liabilities | 71 | 76 | 226 | 306 | 165 | 167 | 200 | 443 | 2,532 | 1,381 |
| Non Current Liabilities | 25 | 60 | 349 | 79 | 91 | 91 | 164 | 1,003 | 1,286 | 2,380 |
| Total Equity | 302 | 591 | 886 | 1,169 | 1,296 | 1,576 | 1,908 | 2,221 | 3,222 | 3,272 |
| Reserve & Surplus | 302 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,894 | 2,182 | 2,573 | 2,841 |
| Share Capital | 0 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 | 106 |
| Investing Activities | -92 | -44 | -185 | -590 | -5 | 123 | -323 | -320 | -975 | -1,828 | -78 |
| Operating Activities | 90 | 132 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1,065 |
| Financing Activities | 1 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 | -881 |
Share Holding
| % Holding | Jan 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 55.55 % | 54.13 % | 52.69 % | 52.68 % | 52.66 % | 52.66 % | 52.30 % | 52.29 % | 52.70 % | 52.86 % | 52.86 % | 54.91 % | 54.90 % | 54.90 % | 54.88 % | 54.87 % | 54.86 % | 54.85 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 13.20 % | 0.00 % | 14.27 % | 14.59 % | 8.01 % | 8.35 % | 8.43 % |
| DIIs | 10.52 % | 9.25 % | 9.66 % | 9.57 % | 9.99 % | 10.11 % | 10.36 % | 10.38 % | 9.94 % | 10.02 % | 10.28 % | 14.53 % | 13.86 % | 15.63 % | 16.23 % | 18.64 % | 18.06 % | 18.07 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 22.42 % | 23.28 % | 23.23 % | 23.29 % | 23.19 % | 23.14 % | 21.34 % | 21.27 % | 21.45 % | 21.66 % | 22.07 % | 15.47 % | 15.67 % | 14.24 % | 13.53 % | 10.51 % | 9.29 % | 9.16 % |
| Others | 11.51 % | 13.34 % | 14.42 % | 14.46 % | 14.16 % | 14.09 % | 16.01 % | 16.07 % | 15.90 % | 15.46 % | 14.79 % | 1.90 % | 15.57 % | 0.95 % | 0.77 % | 7.96 % | 9.43 % | 9.49 % |
| No of Share Holders | 29,195 | 41,470 | 46,477 | 49,833 | 54,223 | 57,061 | 51,639 | 48,055 | 46,746 | 45,931 | 44,169 | 42,245 | 46,496 | 51,753 | 44,176 | 46,346 | 53,314 | 50,087 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 2.87 | 5.5 | 6.01 | 7.35 | 0.00 | 7.35 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 | 0.8 | 1.05 | 0.87 | 0.00 | 0.42 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 25 Jul 2025 |  Annual General Meeting | NA | 25 Jul 2025 | 1,679.60 | 1,745.90 |
| 19 May 2025 |  Quarterly Result Announcement | NA | 19 May 2025 | 1,402.05 | 1,465.15 |
| 13 Feb 2025 |  Dividend | ₹ 7.35 /share | 13 Feb 2025 | 1,460.10 | 1,301.85 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,157.90 | 1,248.00 |
| 25 Oct 2024 | Quarterly Result Announcement | NA | 25 Oct 2024 | 1,329.15 | 1,282.30 |
| 25 Sept 2024 | Annual General Meeting | NA | 25 Sept 2024 | 1,454.10 | 1,311.75 |
| 16 Aug 2022 | Dividend | ₹ 7.35 /share | 11 Aug 2022 | 696.65 | 695.05 |
| 06 Aug 2021 | Dividend | ₹ 6.01 /share | 05 Aug 2021 | 742.15 | 747.90 |
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Jul 03, 2025Book Closure For Annual General MeetingJul 02, 2025
Jul 02, 2025Shareholders Meeting - Annual General Meeting - July 25 2025Jul 02, 2025
Jul 02, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 02, 2025
Jul 02, 2025Reg. 34 (1) Annual Report.Jul 02, 2025
Jul 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Jul 02, 2025Board Meeting Outcome for The Meeting Held On June 30 2025Jun 30, 2025
Jun 30, 2025Board Meeting Outcome for The Meeting Held On June 30 2025Jun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Corporate PresentationJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 11, 2025
Jun 11, 2025Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD Jun 09, 2025
Jun 09, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 04, 2025
Jun 04, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 19, 2025
May 19, 2025Revision In Outcome Of Board MeetingMay 19, 2025
May 19, 2025Financial Results For Quarter And Year Ended March 31 2025May 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 19, 2025
May 19, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
May 13, 2025Board Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025May 13, 2025
May 13, 2025Update On Credit Rating Of Eris Therapeutics LimitedMay 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Credit RatingMay 09, 2025
May 09, 2025 Announcement Under Regulation 30 (LODR)-Credit Rating Of Eris Therapeutics LimitedMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Credit RatingMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Apr 29, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 24, 2025
Apr 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 05, 2025
Apr 05, 2025Corporate GuaranteeMar 31, 2025
Mar 31, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Clarification With Respect To Increase In VolumeMar 21, 2025
Mar 21, 2025Clarification sought from Eris Lifesciences LtdMar 21, 2025
Mar 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 07, 2025
Mar 07, 2025Announcement Under Regulation 30 - Sale Of SubsidiariesMar 06, 2025
Mar 06, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 06, 2025
Mar 06, 2025Announcement Under Regulation 30 - Update On Acquisition Of 30% Equity Stake In Levim Lifetech Private LimitedFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Feb 24, 2025Announcement Under Regulation 30 - Redemption Of 43750 8% Secured Unlisted Redeemable Non-Convertible DebenturesFeb 21, 2025
Feb 21, 2025Announcement Under Regulation 30 - Availing Credit FacilitiesFeb 21, 2025
Feb 21, 2025Corporate GuaranteeFeb 19, 2025
Feb 19, 2025Corporate PresentationFeb 19, 2025
Feb 19, 2025Technical Indicators
RSI(14)
Neutral 58.37
ATR(14)
Volatile 64.78
STOCH(9,6)
Overbought 80.79
STOCH RSI(14)
Overbought 85.14
MACD(12,26)
Bullish 0.27
ADX(14)
Strong Trend 29.27
UO(9)
Bearish 56.74
ROC(12)
Uptrend And Accelerating 7.94
WillR(14)
Overbought -13.46
Mutual Fund Holdings
UTI Flexi Cap Fund Direct-Growth 
Franklin India Opportunities Direct Fund-Growth 
HDFC Business Cycle Fund Direct - Growth 
TRUSTMF Small Cap Fund Direct-Growth 
Nippon India Nifty 500 Momentum 50 Index Fund Direct-Growth 
HSBC Small Cap Fund Direct-Growth 
Motilal Oswal Nifty 500 Momentum 50 Index Fund Direct-Growth 
Bank of India Consumption Fund Direct-Growth 
Aditya Birla Sun Life Equity Hybrid '95 Fund Direct-Growth 
Bandhan Small Cap Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Axis Nifty500 Momentum 50 Index Fund Direct-Growth 
Quantum Small Cap Fund Direct - Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth About Eris Lifesciences
Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands and a distribution network of 22 sales depots, 2,059 stockists, and over 500,000 retail chemists. Eris has expanded through acquisitions and launches of new divisions. It has five wholly-owned subsidiaries and has acquired various brands and businesses in recent years, including dermatology and cosmetology brands. The company also produces human insulin and has entered the anti-thrombotics segment.
Listing Date
29 Jun, 2017(8 Years,
-14 days)
Website
Chairperson NameAmit Indubhushan Bakshi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
